Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
B-RAF is frequently mutated in solid tumors, resulting in activation of the MEK/ERK signaling pathway and ultimately tumor cell growth and survival. MEK inhibition in these cells results in cell cycle arrest and cytostasis. Here, we have shown that MEK inhibition also triggers limited apoptosis of human tumor cell lines with B-RAF mutations and that this effect was dependent on upregulation and dephosphorylation of the proapoptotic, Bcl-2 homology 3-only (BH3-only) Bcl-2 family member Bim. However, upregulation of Bim was insufficient for extensive apoptosis and was countered by overexpression of Bcl-2. To overcome apoptotic resistance, we treated the B-RAF mutant cells both with MEK inhibitors and with the BH3 mimetic ABT-737, resulting in profound synergism and extensive tumor cell death. This treatment was successful because of both efficient antagonism of the prosurvival Bcl-2 family member Mcl-1 by Bim and inhibition of Bcl-2 and Bcl-x(L) by ABT-737. Critically, addition of ABT-737 converted the predominantly cytostatic effect of MEK inhibition to a cytotoxic effect, causing long-term tumor regression in mice xenografted with human tumor cell lines. Thus, the therapeutic efficacy of MEK inhibition requires concurrent unleashing of apoptosis by a BH3 mimetic and represents a potent combination treatment for tumors harboring B-RAF mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Suppression of MEK/ERK signaling leads to the accumulation of the pro-apoptotic BCL-2 family protein BIM, which is critical for inducing apoptosis in response to an array of targeted therapies14,15.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [14]
In the citing paper
“Indeed, ERK1/2 pathway inhibitors combine with navitoclax, or the close analogue ABT-737, to induce colorectal cancer (CRC) apoptosis and tumour regression in vivo11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“Combining BRAFi or MEKi with pan-BCL2/BCL-w/BCL-XL inhibitors causes strong synergistic cell death of CRC, NSCLC and pancreatic cells and tumour regressions11,25,26.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“This is also true in other tumour lineages, such as CRC; however, whereas increased BIM and BMF primed CRC cells to undergo substantial apoptosis following treatment with the BCL2/BCL-w/BCL-XL inhibitor navitoclax/ABT-26311,25,26, this combination was notably less effective in melanoma11,27,28.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [25]
In the citing paper
“An increase in the formation of MCL1:BIM complexes has been documented after exposure of BRAF-mutant melanoma cells to the BCL2/BCL-XL inhibitor ABT-737 (20) and in KRAS-mutant cells of different origin treated with navitoclax (18, 21).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [20]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Strasser, A., O'Connor, L., & Dixit, V. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.217 · Cited by 1,351
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
Self-citation
Research works printed but not linked: 3
- Cohen, 2002, Clin. Cancer Res., 8, 3728
- Brose, 2002, Cancer Res., 62, 6997
- Bos, 1989, Cancer Res., 49, 4682
Cited by
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Self-citationTargeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Self-citationHata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
“Notably, prior laboratory studies have demonstrated that dual BCL-XL and BCL-2 inhibitors can enhance the apoptotic activity of targeted therapies that induce apoptosis by inducing BIM 17,30,31 , presumably by decreasing the capacity of BCL-XL to neutralize BIM.”
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Self-citationThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
“Thus, as discussed further below, suppression of BH3-only protein activity by activation of the MEK–ERK and PI3K–AKT signaling pathways may play a central role in the survival of cancers driven by constitutively activated oncogenic kinases such as EGFR (84–88), BRAF (89), KRAS (90), and BCR–ABL (91).”
InfluentialScholl, C., Fröhling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.017 · Cited by 538
The BCL-2 protein family, BH3-mimetics and cancer therapy
Delbridge, A. R. D., & Strasser, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.50 · Cited by 531
Self-citationDeciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Strasser, A., Cory, S., & Adams, J. M. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.307 · Cited by 532
Self-citationBCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Self-citationThe role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy
Kelly, P. N., & Strasser, A. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.17 · Cited by 453
Self-citationCorcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Self-citationBH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Self-citationBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283
“Other successful targeted therapy paradigms have also demonstrated an integral role for BIM in promoting apoptosis in response to targeted therapies, including BRAF-mutant colorectal cancers (13), BRAF-mutant melanoma cancers (14, 24, 25), Bcr-Abl–translocated chronic myeloid leukemia (CML) cancers (15), and EML4-ALK–…”
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242
“Consistent with expectations based on the published literature (22, 23), combined GDC-0973 and GDC-0941 treatment increased Bim levels via several complementary mechanisms, including gene expression, BimEL phosphorylation, and Bim protein stabilization.”
MethodHaq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K., Porter, D., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 222
“MEK inhibitors synergized with the BH3 mimetic ABT-737 in BRAF mutant colon cancer cell lines (44).”
BackgroundNew frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
Long, J. S., & Ryan, K. M. (2012) · Oncogene · doi:10.1038/onc.2012.7 · Cited by 214
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Lopez, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Roman, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 196
Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Oakes, S. R., Vaillant, F., Lim, E., Lee, L., Breslin, K., Feleppa, F., Deb, S., Ritchie, M. E., Takano, E., Ward, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104778108 · Cited by 193
Self-citationBH3-only proteins in apoptosis at a glance
Happo, L., Strasser, A., & Cory, S. (2012) · Journal of Cell Science · doi:10.1242/jcs.090514 · Cited by 193
Self-citationBCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Lee, E. F., Harris, T. J., Tran, S., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1568-3 · Cited by 185
Self-citationUnleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
Self-citationHeintz, N. H., Janssen-Heininger, Y. M. W., & Mossman, B. T. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0206tr · Cited by 182
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · The FEBS Journal · doi:10.1111/febs.14122 · Cited by 170
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Correia, C., Lee, S.-H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 166
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Biechele, T. L., Kulikauskas, R. M., Toroni, R. A., Lucero, O. M., Swift, R. D., James, R. G., Robin, N. C., Dawson, D. W., Moon, R. T., & Chien, A. J. (2012) · Science Signaling · doi:10.1126/scisignal.2002274 · Cited by 157
MAP kinase signaling and inhibition in melanoma
Sullivan, R. J., & Flaherty, K. T. (2012) · Oncogene · doi:10.1038/onc.2012.345 · Cited by 173
Bim and Bmf in tissue homeostasis and malignant disease
Piñon, J. D., Labi, V, Egle, A., & Villunger, A. (2008) · Oncogene · doi:10.1038/onc.2009.42 · Cited by 148
Konopleva, M., Milella, M., Ruvolo, P., Watts, J. C., Ricciardi, M. R., Korchin, B., McQueen, T., Bornmann, W., Tsao, T., Bergamo, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.287 · Cited by 139
RetractedUnderstanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
Smalley, K. S. M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.177 · Cited by 159
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M. W., Bollag, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 135
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M., & Letai, A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 128
Targeting BCL2-Proteins for the Treatment of Solid Tumours
Vogler, M. (2014) · Advances in Medicine · doi:10.1155/2014/943648 · Cited by 117
Jiang, C. C., Lai, F., Thorne, R. F., Yang, F., Liu, H., Hersey, P., & Zhang, X. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2225 · Cited by 117
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma
Richter-Larrea, J. A., Robles, E. F., Fresquet, V., Beltran, E., Rullan, A. J., Agirre, X., Calasanz, M. J., Panizo, C., Richter, J. A., Hernandez, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268003 · Cited by 113
Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma
Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017) · Blood · doi:10.1182/blood-2016-10-745059 · Cited by 113
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment
Elkholi, R., Floros, K. V., & Chipuk, J. E. (2011) · Genes & Cancer · doi:10.1177/1947601911417177 · Cited by 111
Happo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G., Michalak, E. M., Vandenberg, C. J., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280818 · Cited by 107
Self-citationDenoyelle, C., Lambert, B., Meryet‐Figuière, M., Vigneron, N., Brotin, É., Lecerf, C., Abeilard, E., Giffard, F., Louis, M.-H., Gauduchon, P., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.389 · Cited by 114
Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma
Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A., & Wellbrock, C. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs471 · Cited by 106
Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Shao, H., Jing, K., Mahmoud, E., Huang, H., Fang, X., & Yu, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0066 · Cited by 110
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Carrington, E. M., Vikstrom, I. B., Light, A., Sutherland, R. M., Londrigan, S. L., Mason, K. D., Huang, D. C. S., Lew, A. M., & Tarlinton, D. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005256107 · Cited by 103
The Role of the Apoptotic Machinery in Tumor Suppression
Delbridge, A. R. D., Valente, L. J., & Strasser, A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008789 · Cited by 102
Self-citationJiang, C. C., Lai, F., Tay, K. H., Croft, A. J., Rizos, H., Becker, T. M., Yang, F., Liu, H., Thorne, R. F., Hersey, P., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.48 · Cited by 106
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M. A., & Cook, S. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07329.x · Cited by 108
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., Minna, J. D., Fang, B., & Roth, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3647 · Cited by 103
Nangia, V., Siddiqui, F. M., Caenepeel, S., Timonina, D., Bilton, S. J., Phan, N., Gomez-Caraballo, M., Archibald, H. L., Li, C., Fraser, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0277 · Cited by 94
“A number of studies have demonstrated that the BCL2/ BCL-xL inhibitors ABT-737 and ABT-263 (navitoclax) can synergize with targeted therapies such as EGFR inhibitors in NSCLC (29–31) and MEK inhibitors in BRAF melanoma (32) and KRAS-mutant cancers (11).”
BackgroundThe Essential Role of Evasion from Cell Death in Cancer
Kelly, G. L., & Strasser, A. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00002-7 · Cited by 113
Self-citationBH3-only protein BIM: An emerging target in chemotherapy
Shukla, S., Saxena, S., Singh, B. K., & Kakkar, P. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.09.002 · Cited by 94
Holt, S. V., Logie, A., Davies, B. R., Alferez, D., Runswick, S., Fenton, S., Chresta, C. M., Gu, Y., Zhang, J., Wu, Y.-L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1780 · Cited by 86
Tan, N., Wong, M., Nannini, M. A., Hong, R., Lee, L. B., Price, S., Williams, K., Savy, P. P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 80
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Mukherjee, N., Skees, J., Todd, K. J., West, D. A., Lambert, K. A., Robinson, W. A., Amato, C. M., Couts, K. L., Gulick, R. J. V., MacBeth, M. L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2646-2 · Cited by 81
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 86
BCL-2: Long and winding path from discovery to therapeutic target
Schenk, R. L., Strasser, A., & Dewson, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.100 · Cited by 77
Self-citationTanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011) · Oncogene · doi:10.1038/onc.2011.111 · Cited by 70
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 75
Stauber, R. H., Knauer, S. K., Habtemichael, N., Bier, C., Unruhe, B., Weisheit, S., Spange, S., Nonnenmacher, F., Fetz, V., Ginter, T., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.430 · Cited by 74
Mitochondria as Therapeutic Targets for the Treatment of Malignant Disease
Fulda, S., & Kroemer, G. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4078 · Cited by 69
How to unleash mitochondrial apoptotic blockades to kill cancers?
Deng, J. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.08.005 · Cited by 69
Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
Mohana‐Kumaran, N., Hill, D. S., Allen, J. D., & Haass, N. K. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12242 · Cited by 65
Middleton, G., Yang, Y., Campbell, C. D., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3579 · Cited by 63
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 72
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., Kantrow, S., Splittgerber, R. C., Short, S. P., Sobolik, T., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1122 · Cited by 62
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors
Liu, Q., & Wang, H. (2012) · Communicative & Integrative Biology · doi:10.4161/cib.21554 · Cited by 67
Sánchez-Hernández, I., Baquero, P., Calleros, L., & Chiloeches, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.037 · Cited by 68
Dai, H., Ding, H., Meng, X. W., Peterson, K. L., Schneider, P. A., Karp, J. E., & Kaufmann, S. H. (2015) · Genes & Development · doi:10.1101/gad.267997.115 · Cited by 68
Sale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58
Wroblewski, D., Mijatov, B., Mohana-Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs330 · Cited by 57
Jebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 66
Shen, A., Wang, L., Huang, M., Sun, J., Chen, Y., Shen, Y., Yang, X., Wang, X., Ding, J., & Geng, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2743 · Cited by 65
Serasinghe, M. N., Missert, D. J., Asciolla, J. J., Podgrabinska, S., Wieder, S. Y., Izadmehr, S., Belbin, G., Skobe, M., & Chipuk, J. E. (2015) · Oncogene · doi:10.1038/onc.2014.21 · Cited by 56
Anvekar, R. A., Asciolla, J. J., Missert, D. J., & Chipuk, J. E. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00034 · Cited by 65
BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-021-00816-w · Cited by 52
Will, B., Siddiqi, T., Alberich-Jordà, M., Shimamura, T., Luptakova, K., Staber, P. B., Costa, D. B., Steidl, U. G., Tenen, D. G., & Kobayashi, S. S. (2010) · Blood · doi:10.1182/blood-2009-03-209544 · Cited by 56
Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0413 · Cited by 52
Zall, H., Weber, A., Besch, R., Zantl, N., & Häcker, G. A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-164 · Cited by 59
Frederick, D. T., Salas Fragomeni, R. A., Schalck, A., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 49
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim
Park, S. H., Ito, K., Olcott, W., Katsyv, I., Halstead-Nussloch, G., & Irie, H. Y. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0594-z · Cited by 50
Pétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 57
Tao, M., Shi, Y., Tang, L., Wang, Y., Fang, L., Jiang, W., Lin, T., Qiu, A., Zhuang, S., & Liu, N. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00480.2018 · Cited by 56
Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis
Simonin, K., N’Diaye, M., Lheureux, S., Loussouarn, C., Dutoit, S., Briand, M., Giffard, F., Brotin, É., Blanc‐Fournier, C., & Poulain, L. (2013) · APOPTOSIS · doi:10.1007/s10495-012-0799-x · Cited by 46
Byron, S. A., Loch, D. C., Wellens, C. L., Wortmann, A., Wu, J., Wang, J., Nomoto, K., & Pollock, P. M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-75 · Cited by 46
Kim, Y., Tsang, T., Anderson, G. R., Posimo, J. M., & Brady, D. C. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1784 · Cited by 51
Role of the pro-survival molecule Bfl-1 in melanoma
Hind, C. K., Carter, M. J., Harris, C. L., Chan, H.-H., James, S., & Cragg, M. S. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.11.015 · Cited by 44
Self-citationGordon, P. M., & Fisher, D. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078592 · Cited by 44
Greenhough, A., Wallam, C. A., Hicks, D. J., Moorghen, M., Williams, A. C., & Paraskeva, C. (2010) · Oncogene · doi:10.1038/onc.2010.94 · Cited by 49
Exploiting mitochondrial apoptosis for the treatment of cancer
Fulda, S. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.05.001 · Cited by 45
Liu, Y. L., Lai, F., Wilmott, J. S., Yan, X. G., Liu, X. Y., Luan, Q., Guo, S. T., Jiang, C. C., Tseng, H.-Y., Scolyer, R. A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2616 · Cited by 40
“The finding that oncogenic activation of MEK/ ERK signaling is responsible for Noxa upregulation in melanoma cells is similarly intriguing, as oncogenic activation of the MEK/ERK pathway is known to be a major driver of the pathogenesis of melanoma that suppresses apoptosis [1, 2, 6, 7].”
BackgroundDing, H., Peterson, K. L., Correia, C., Koh, B. D., Schneider, P., Nowakowski, G. S., & Kaufmann, S. H. (2016) · Leukemia · doi:10.1038/leu.2016.357 · Cited by 44
Kinetic Heterogeneity of Cancer Cell Fractional Killing
Inde, Z., Forcina, G. C., Denton, K., & Dixon, S. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107845 · Cited by 39
Pikman, Y., Tasian, S. K., Sulis, M. L., Stevenson, K. E., Blonquist, T. M., Winger, B. A., Cooper, T. M., Pauly, M. G., Maloney, K. W., Burke, M. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0564 · Cited by 40
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 44
Adjei, A. A., LoRusso, P. M., Ribas, A., Sosman, J. A., Pavlick, A. C., Dy, G. K., Zhou, X., Gangolli, E. A., Kneissl, M., Faucette, S. R., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0391-2 · Cited by 44
Vachtenheim, J., & Ondrušová, Ľ. (2015) · Experimental Dermatology · doi:10.1111/exd.12724 · Cited by 40
Clybouw, C., Mérino, D., Nebl, T., Masson, F., Robati, M., O’Reilly, L. A., Hübner, A., Davis, R. J., Strasser, A., & Bouillet, P. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.198 · Cited by 41
Self-citationKorfi, K., Smith, M., Swan, J., Somervaille, T. C. P., Dhomen, N. S., & Marais, R. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.70 · Cited by 38
Metadata
- Authors
- Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L.
- Affiliations
- Walter and Eliza Hall Institute of Medical Research (AU)
- University of Southampton (GB)
- Corresponding author
- Strasser, Andreas
- Venue
- Journal of Clinical Investigation
- Published
- 2008-11-03
- Volume
- 118
- Issue
- 11
- Pages
- 3651-3659
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2571034
- OpenAlex
- W2167334545
- Cited by
- 207
- References
- 36
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 12 · 2019: 10 · 2018: 5 · 2017: 8 · 2016: 13 · 2015: 18 · 2014: 15 · 2013: 17 · 2012: 19
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Institutes of Health (CA 43540)
- Medical Research Council
- National Health and Medical Research Council (257502)
- National Cancer Institute (#CA 80188, R01CA043540, CA 43540, R01CA080188)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- BRAF mutation, MEK inhibitors, BH3 mimetics, ABT-737, building information modeling, Bcl-2, Mcl-1, Bcl-xL, apoptosis, MEK/ERK signaling, combination therapy, tumor regression, cytostasis, Bcl-2 family proteins
- MeSH terms
- Bcl-2-Like Protein 11, Biphenyl Compounds, Humans, Membrane Proteins, Mutation, Neoplasms, Nitrophenols, Piperazines, Proto-Oncogene Proteins, Sulfonamides, Molecular Mimicry, HT29 Cells, Proto-Oncogene Proteins c-bcl-2, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.